Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006440
Abstract: Key Points • Treatment with IL-15 before alemtuzumab was safe and led to decreased number and proliferative activity of T-cell leukemic cells.• IL-15 was associated with increased activation and proliferation of patient-derived NK and CD8+… read more here.
Keywords: cell; mediated adcc; augments cell; interleukin augments ... See more keywords